Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(3):292–296. doi: 10.1111/j.1349-7006.2003.tb01435.x

Ovarian cancer incidence and survival by histologic type in Osaka, Japan

Akiko Loka 1,✉, Hideaki Tsukuma 1, Wakiko Ajiki 1, Akira Oshima 1
PMCID: PMC11160271  PMID: 12824924

Abstract

The incidence of ovarian cancer among Japanese has increased since the 1970s. Histologic diversity is a characteristic of this cancer. However, there has been no population‐based study made on the incidence and survival by histologic type. Osaka Cancer Registry's data was used for incidence and survival analyses of ovarian cancer by histologic type in this study. Seven thousand one hundred sixty‐seven incident cases were registered during the period 1975 to 1998. According to the IARC's histologic classi‐fication, types of ovarian cancer were classified into five categories. Survival analysis was restricted to the reported 2431 cases who lived in Osaka Prefecture (except for Osaka City) and were diagnosed in 1975–1994, since active follow‐up data on vital status 5 years after the diagnosis were available. The age‐standardized incidence rate of ovarian cancer increased from 4.0 to 5.4 per 100 000 women (standard: world population) in Osaka during the period 1975–1998. Carcinoma, the major histologic category, also increased (from 3.4 to 4.8 per 100 000 women), while sex cordstromal tumors decreased after 1980 and germ cell tumors remained stable. The 5‐year relative survival was 36.4% for ovarian cancer patients diagnosed in 1975–1994. The survival for carcinoma was 38.3%, which was lower than that in sex cord‐stromal tumors or germ cell tumors (55.3% and 58.6%, respectively). The increase in the incidence of ovarian cancer was caused by the increase in carcinoma. The relative 5‐year survival of ovarian cancer improved over the period, but was different by histologic type. (Cancer Sci 2003; 94: 292–296)

References

  • 1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents. Volume VII. In: IARC scientific publ No 143. Lyon , France : International Agency for Research on Cancer; 1997. [Google Scholar]
  • 2. Herrinton LJ, Stanford JL, Schwartz, SM , Weiss NS. Ovarian cancer incidence among Asian migrants to the United States and their descendants. J Natl Cancer Inst 1994; 86: 1336–9. [DOI] [PubMed] [Google Scholar]
  • 3. Weiss, NS , Peterson AS. Racial variation in the incidence of ovarian cancer in the United States. Am J Epidemiol 1978; 107: 91–5. [DOI] [PubMed] [Google Scholar]
  • 4. Tamakoshi K, Kondo T, Yatsuya H, Hori Y, Kikkawa F, Toyoshima H. Trends in the mortality (1950–1997) and incidence (1975–1993) of malignant ovarian neoplasm among Japanese women: analyses by age, time, and birth cohort. Gynecol Oncol 2001; 83: 64–71. [DOI] [PubMed] [Google Scholar]
  • 5. Mant JWF, Vessey MP. Ovarian and endometrial cancers. In: Doll R, Fraumeni JF Jr, Muir CS, editors. Trends in cancer incidence and mortality. New York : Cold Spring Harbor Laboratory Press; 1994. p. 287–307. [Google Scholar]
  • 6. dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995; 72: 485–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Adami HO, Bergstrom R, Persson I, Sparen P. The incidence of ovarian cancer in Sweden, 1960–1984. Am J Epidemiol 1990; 132: 446–52. [DOI] [PubMed] [Google Scholar]
  • 8. Ewertz M, Kjaer SK. Ovarian cancer incidence and mortality in Denmark, 1943–1982. Int J Cancer 1988; 42: 690–6. [DOI] [PubMed] [Google Scholar]
  • 9. Estev J, Benhamou E, Raymond L. Statistical methods in cancer research. Volume IV: Descriptive epidemiology. In: IARC Scientific Publ No 128. Lyon , France : International Agency for Research on Cancer; 1994. p. 231–45. [PubMed] [Google Scholar]
  • 10. Osaka Prefectural Department of Public Health and Welfare , Osaka Medical Association , Osaka Medical Center for Cancer and Cardiovascular Diseases . Annual report of Osaka cancer registry No 64–Cancer incidence and medical care in Osaka in 1998 and the survival in 1994–.OPDPHW; 2001. (in Japanese).
  • 11. Thorogood M, Villard‐Mackintosh L. Combined oral contraceptives: risks and benefits. Br Med Bull 1993; 49: 124–39. [DOI] [PubMed] [Google Scholar]
  • 12. Cancer and Steroid Hormone Study . The reduction in risk of ovarian cancer associated with oral‐contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316: 650–5. [DOI] [PubMed] [Google Scholar]
  • 13. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80: 708–14. [PubMed] [Google Scholar]
  • 14. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140: 585–97. [DOI] [PubMed] [Google Scholar]
  • 15. Villard‐Mackintosh L, Vessey MP, Jones L. The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. Br J Obstet Gynaecol 1989; 96:783–8. [DOI] [PubMed] [Google Scholar]
  • 16. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemol 1992; 136: 1204–11. [DOI] [PubMed] [Google Scholar]
  • 17. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case‐control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1212–20. [DOI] [PubMed] [Google Scholar]
  • 18. Voest EE, Van Houwelingen JC, Neijt JP. A meta‐analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log relative risk) as main objectives. Eur J Cancer Clin Oncol 1989; 25: 711–20. [DOI] [PubMed] [Google Scholar]
  • 19. Richardson GS, Scully RE, Nikrui N, Nelson JH Jr. Common epithelial cancer of the ovary. N Engl J Med 1985; 312: 415–24. [DOI] [PubMed] [Google Scholar]
  • 20. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major J Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–7. [DOI] [PubMed] [Google Scholar]
  • 21. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101–4. [PubMed] [Google Scholar]
  • 22. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413–20. [PubMed] [Google Scholar]
  • 23. Spring S. SEER*Stat Statistical software version 4.2. National Cancer Institute; 2002. [Google Scholar]
  • 24. Oshima A, Kitagawa T, Ajiki W, Tsukuma H, Takenaka S, Iura A. Survival of testicular cancer patients in Osaka, Japan. Jpn J Clin Oncol 2001; 31: 438–43. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES